Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method
- 108 Downloads
Hairy cell leukemia (HCL) is a rare B-cell lymphoid malignancy that is difficult to distinguish from other morphological variants. The frequency of HCL has not been determined accurately in Japan. Recent studies revealed that the BRAF V600E mutation is the causal genetic event in HCL. We assessed the BRAF mutation in Japanese patients with HCL and related diseases using the quenching probe (QP) method, a single-nucleotide polymorphism detection system, and evaluated the incidence rate of HCL among Japanese patients with chronic lymphocytic leukemia, and related diseases. We identified 18 cases (33.3%) harboring the BRAF mutation among 54 patients diagnosed with, or suspected of having HCL. Of BRAF V600E-positive patients, 7 were only detected using the QP method, not by direct sequencing, whereas 11 were positive using both tests. In a larger cohort of Japanese patients diagnosed with chronic lymphoid leukemia or related diseases, the frequency of HCL was 4%. Patients with the BRAF V600E mutation had a significantly higher frequency of neutropenia, thrombocytopenia, and elevated soluble interleukin-2 receptor and common B-cell surface markers than patients without the mutation. Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.
KeywordsBRAF V600E Hairy cell leukemia Low-grade B-cell malignancy Quenching probe Japan
The authors thank all of the patients and all of the investigators at participating institutions.
Compliance with ethical standards
Conflict of interest
The authors declare no potential conflicts of interest.
- 4.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: World Heal. Organ. Classification Tumours Haematop. Lymphoid Tissue; 2008.Google Scholar
- 22.Suzuki SI, Matsusaka S, Hirai M, Shibata H, Takagi K, Mizunuma N, et al. A novel approach to detect KRAS/BRAF mutation for colon cancer: highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. Int J Oncol. 2015;47:97–105.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, et al. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer. 2015;15:258–66.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Haroche J, Charlotte F, Arnaud L, Von Deimling A, Hélias-rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses brief report high prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700–3.CrossRefPubMedGoogle Scholar